Mô hình biểu hiện khác biệt của hai isoform gen TNFSF15 trong ung thư đại tràng ở người

Arnold M, Sierra MS, Laversanne M, et al. Global patterns and trends in colorectal cancer incidence and mortality. Gut. 2017;66:683–691. Hadjipetrou A, Anyfantakis D, Galanakis CG, Kastanakis M, Kastanakis S. Colorectal cancer, screening and primary care: a mini literature review. World J Gastroenterol. 2017;23:6049–6058. Migone TS, Zhang J, Luo X, et al. TL1A is a TNF-like ligand for DR3 and TR6/DcR3 and functions as a T cell costimulator. Immunity. 2002;16:479–492. Metheny-Barlow LJ, Li LY. Vascular endothelial growth inhibitor (VEGI), an endogenous negative regulator of angiogenesis. Semin Ophthalmol. 2006;21:49–58. Chew LJ, Pan H, Yu J, et al. A novel secreted splice variant of vascular endothelial cell growth inhibitor. FASEB J. 2002;16:742–744. Richard AC, Ferdinand JR, Meylan F, et al. The TNF-family cytokine TL1A: from lymphocyte costimulator to disease co-conspirator. J Leukoc Biol. 2015;98:333–345. Slebioda TJ, Bojarska-Junak A, Stanislawowski M, et al. TL1A as a potential local inducer of IL17A expression in colon mucosa of inflammatory bowel disease patients. Scand J Immunol. 2015;82:352–360. Slebioda TJ, Kmiec Z. Tumour necrosis factor superfamily members in the pathogenesis of inflammatory bowel disease. Mediators Inflamm. 2014;2014:325129. Zhang N, Sanders AJ, Ye L, Jiang WG. Vascular endothelial growth inhibitor in human cancer (Review). Int J Mol Med. 2009;24:3–8. Tian F, Liang PH, Li LY. Inhibition of endothelial progenitor cell differentiation by VEGI. Blood. 2009;113:5352–5360. Hou W, Medynski D, Wu S, Lin X, Li LY. VEGI-192, a new isoform of TNFSF15, specifically eliminates tumor vascular endothelial cells and suppresses tumor growth. Clin Cancer Res. 2005;11:5595–5602. Zhang N, Wu P, Wu L, et al. The differential expression of vascular endothelial growth inhibitor isoforms, VEGI251, VEGI174 and VEGI192 in human clear-cell renal cell carcinoma. Cancer Genomics Proteomics. 2013;10:47–53. Zhao Q, Liu T, Hong B, et al. Vascular Endothelial Growth Inhibitor, a Cytokine of the Tumor Necrosis Factor Family, is Associated With Epithelial-Mesenchymal Transition in Renal Cell Carcinoma. Applied immunohistochemistry & molecular morphology: AIMM; 2017. Jia W, Sander AJ, Jia G, et al. Vascular endothelial growth inhibitor (VEGI) is an independent indicator for invasion in human pituitary adenomas. Anticancer Res. 2013;33:3815–3822. Slebioda TJ, Rowley TF, Ferdinand JR, et al. Triggering of TNFRSF25 promotes CD8(+) T-cell responses and anti-tumor immunity. Eur J Immunol. 2011;41:2606–2611. Zhang Z, Yu D, Lu J, et al. Functional genetic variants of TNFSF15 and their association with gastric adenocarcinoma: a case–control study. PLoS ONE. 2014;9:e108321. Sun Y, Irwanto A, Toyo-Oka L, et al. Fine-mapping analysis revealed complex pleiotropic effect and tissue-specific regulatory mechanism of TNFSF15 in primary biliary cholangitis. Crohn’s disease and leprosy. Sci Rep. 2016;6:31429. Ye BD, Choi H, Hong M, et al. Identification of ten additional susceptibility loci for ulcerative colitis through immunochip analysis in Koreans. Inflamm Bowel Dis. 2016;22:13–19. Kepiro L, Szell M, Kovacs L, et al. Genetic risk and protective factors of TNFSF15 gene variants detected using single nucleotide polymorphisms in Hungarians with psoriasis and psoriatic arthritis. Hum Immunol. 2014;75:159–162. Simon K. Colorectal cancer development and advances in screening. Clin Interv Aging. 2016;11:967–976. Boland CR, Goel A. Microsatellite instability in colorectal cancer. Gastroenterology. 2010;138:2073–2087.e3. van de Velde CJ, Boelens PG, Borras JM, et al. EURECCA colorectal: multidisciplinary management: European consensus conference colon & rectum. Eur J Cancer. 2014;50:1.e1–1.e34. Park MH, Song MJ, Cho MC, et al. Interleukin-32 enhances cytotoxic effect of natural killer cells to cancer cells via activation of death receptor 3. Immunology. 2012;135:63–72. Boland CR, Thibodeau SN, Hamilton SR, et al. A National Cancer Institute Workshop on Microsatellite Instability for cancer detection and familial predisposition: development of international criteria for the determination of microsatellite instability in colorectal cancer. Can Res. 1998;58:5248–5257. Wierzbicki PM, Adrych K, Kartanowicz D, et al. Underexpression of LATS1 TSG in colorectal cancer is associated with promoter hypermethylation. World J Gastroenterol. 2013;19:4363–4373. Janavicius R, Matiukaite D, Jakubauskas A, Griskevicius L. Microsatellite instability detection by high-resolution melting analysis. Clin Chem. 2010;56:1750–1757. Weidner N. Angiogenesis as a predictor of clinical outcome in cancer patients. Hum Pathol. 2000;31:403–405. Bittner S, Knoll G, Ehrenschwender M. Death receptor 3 signaling enhances proliferation of human regulatory T cells. FEBS Lett. 2017;591:1187–1195. Karin M. NF-kappaB as a critical link between inflammation and cancer. Cold Spring Harb Perspect Biol. 2009;1:a000141. Maisey N. Antitumor necrosis factor (TNF-a) antibodies in the treatment of renal cell cancer. Cancer Invest. 2007;25:589–593. Harrison ML, Obermueller E, Maisey NR, et al. Tumor necrosis factor alpha as a new target for renal cell carcinoma: two sequential phase II trials of infliximab at standard and high dose. J Clin Oncol. 2007;25:4542–4549. Balkwill F. TNF-alpha in promotion and progression of cancer. Cancer Metastasis Rev. 2006;25:409–416. Pikarsky E, Porat RM, Stein I, et al. NF-kappaB functions as a tumour promoter in inflammation-associated cancer. Nature. 2004;431:461–466. Moorchung N, Kunwar S, Ahmed KW. An evaluation of nuclear factor kappa B expression in colorectal carcinoma: an analysis of 50 cases. J Cancer Res Ther. 2014;10:631–635. Niu W, Wu Z, Wang J, et al. Tumor necrosis factor ligand-related molecule 1A regulates the occurrence of colitis-associated colorectal cancer. Dig Dis Sci. 2018;63:2341–2350. https://doi.org/10.1007/s10620-018-5126-0. Gout S, Morin C, Houle F, Huot J. Death receptor-3, a new E-Selectin counter-receptor that confers migration and survival advantages to colon carcinoma cells by triggering p38 and ERK MAPK activation. Can Res. 2006;66:9117–9124. Zhang L, Zhang Y, Zhang L, Yang X, Lv Z. Lupeol, a dietary triterpene, inhibited growth, and induced apoptosis through down-regulation of DR3 in SMMC7721 cells. Cancer Invest. 2009;27:163–170. Ge Z, Sanders AJ, Ye L, Mansel RE, Jiang WG. Expression of death receptor-3 in human breast cancer and its functional effects on breast cancer cells in vitro. Oncol Rep. 2013;29:1356–1364. Baskaran K, Pugazhendhi S, Ramakrishna BS. Protective association of tumor necrosis factor superfamily 15 (TNFSF15) polymorphic haplotype with Ulcerative Colitis and Crohn’s disease in an Indian population. PLoS ONE. 2014;9:e114665. Connelly TM, Choi CS, Berg AS, et al. Diverticulitis and Crohn’s disease have distinct but overlapping tumor necrosis superfamily 15 haplotypes. J Surg Res. 2017;214:262–269. Hedl M, Abraham C. A TNFSF15 disease-risk polymorphism increases pattern-recognition receptor-induced signaling through caspase-8-induced IL-1. Proc Natl Acad Sci USA. 2014;111:13451–13456. Bamias G, Martin C 3rd, Marini M, et al. Expression, localization, and functional activity of TL1A, a novel Th1-polarizing cytokine in inflammatory bowel disease. J Immunol. 2003;171:4868–4874. Zhang E, Zhu X, Han S, et al. Increased expression of TNF ligand-related molecule 1A and death receptor 3 in bladder tissues of patients with painful bladder syndrome/interstitial cystitis. Exp Ther Med. 2013;5:282–286.